Amgen, Bind Biosciences deal

Bind and Amgen partnered to develop and commercialize an Accurin therapeutic for solid tumor indications selected by Amgen. Accurins are selective and programmable nanoparticle-encapsulated therapeutics, which are designed to accumulate at the site of disease. Under the deal, Amgen will provide an undisclosed kinase inhibitor and Bind will use its Medicinal Nanoengineering technology to develop an Accurin based on the inhibitor. Bind said the deal aims to create a "kinase inhibitor nanomedicine with optimized therapeutic properties." The company said the deal is "applying for the first time tissue targeting to molecularly targeted drugs." ...